Tectonic Therapeutic Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	20.55	16.65	7.68	7.18	4.63
Research & Development	63.49	41.36	36.97	25.65	10.98
Operating Expenses	84.04	58.02	44.65	32.83	15.61
Operating Income	-84.04	-58.02	-44.65	-32.83	-15.61
Interest Expense	-0.06	-0.11	-0.15	-0.14	-0.45
Interest & Investment Income	11.3	4.26	0.58	0.15	-
Other Non Operating Income (Expenses)	-0.12	-4.12	1.4	0.65	8.1
EBT Excluding Unusual Items	-72.92	-57.98	-42.82	-32.18	-7.96
Other Unusual Items	-	-	-	-	-0.97
Pretax Income	-72.92	-57.98	-42.82	-32.18	-8.93
Income Tax Expense	1.23	-	-	-	-
Earnings From Continuing Operations	-74.15	-57.98	-42.82	-32.18	-8.93
Net Income	-74.15	-57.98	-42.82	-32.18	-8.93
Net Income to Common	-74.15	-57.98	-42.82	-32.18	-8.93
Shares Outstanding (Basic)	18	8	1	3	-
Shares Outstanding (Diluted)	18	8	1	3	-
Shares Change (YoY)	115.81%	569.30%	-49.78%	-	-
EPS (Basic)	-4.05	-6.83	-33.76	-12.74	-
EPS (Diluted)	-4.05	-6.83	-33.76	-12.74	-
Free Cash Flow	-60.29	-59.24	-40.96	-29.73	-14.58
Free Cash Flow Per Share	-3.29	-6.98	-32.29	-11.77	-
EBITDA	-82.66	-56.37	-43.17	-31.82	-15.25
D&A For EBITDA	1.38	1.65	1.48	1.01	0.36
EBIT	-84.04	-58.02	-44.65	-32.83	-15.61

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q